Hypertensive Nephropathy: Clinical Trials

3 trials for Hypertensive Nephropathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 recruiting. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Unknown 2, Recruiting 1

Follow Hypertensive Nephropathy: new trials by email Literature Review of Hypertensive Nephropathy trials Research Report on Hypertensive Nephropathy

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
ACE Reno - Hypertensive Nephropathy, Auto Immune Disorders
Phase 4RecruitingAce Cells Lab Limited3002025-09-202025-09-23
Nighttime Losartan in Continous Ambulatory Peritoneal Dialysis (NVCAPD)
Losartan - Hypertension,Nephropathy
Phase 4UnknownFifth Affiliated Hospital, Sun Yat-Sen University682018-12-012018-11-05
Nighttime Valsartan in Hemodialysis Hypertension
Valsartan - Hypertension;Nephropathy
Phase 4UnknownFifth Affiliated Hospital, Sun Yat-Sen University682018-11-012018-07-20

Narrower conditions

Diabetic Nephropathies (1)  ·  Kidney Diseases (1)  ·  Renal Insufficiency, Chronic (1)

Broader conditions

Chronic Disease (1)  ·  Diabetes Complications (1)  ·  Diabetes Mellitus (1)  ·  Disease Attributes (1)  ·  Endocrine System Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Male Urogenital Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Renal Insufficiency (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Interventions

Losartan (1)  ·  Valsartan (1)  ·  lactitol (1)

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University (2)  ·  Ace Cells Lab Limited (1)

Countries

Egypt (1)

Top investigators

Cheng Wang, Director (2)  ·  Dr. Alaa Abdelkarim M Fouad, MRCPUK SEC (1)